Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy-Reference-Cited by-同舟云学术

Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy

Published:2020-02-04 Issue:5 Volume:86 Page:880-890
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Marcath Lauren A.¹^ORCID,Kidwell Kelley M.²³,Vangipuram Kiran⁴,Gersch Christina L.²,Rae James M.²,Burness Monika L.²⁵,Griggs Jennifer J.²⁵,Van Poznak Catherine²⁵,Hayes Daniel F.²⁵,Smith Ellen M. Lavoie⁶,Henry N. Lynn⁷,Beutler Andreas S.⁸⁹,Hertz Daniel L.⁴^ORCID

Affiliation:

1. Department of PharmacotherapyWashington State University College of Pharmacy and Pharmaceutical Sciences Spokane WA USA

2. University of Michigan Rogel Cancer Center Ann Arbor MI USA

3. Department of BiostatisticsUniversity of Michigan School of Public Health Ann Arbor MI USA

4. Department of Clinical PharmacyUniversity of Michigan College of Pharmacy Ann Arbor MI USA

5. Department of Internal Medicine, Division of Hematology/OncologyUniversity of Michigan Medical School Ann Arbor MI USA

6. Department of Health Behavior and Biological SciencesUniversity of Michigan School of Nursing Ann Arbor MI USA

7. Department of Internal Medicine, Division of OncologyUniversity of Utah School of Medicine Salt Lake City UT USA

8. Department of AnesthesiologyMayo Clinic Rochester MN USA

9. Department of OncologyMayo Clinic Rochester MN USA

Funder

Breast Cancer Research Foundation

National Cancer Institute

National Center for Advancing Translational Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14192

Reference41 articles.

1. Paclitaxel in Breast Cancer

2. SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer

3. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

4. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review

5. Impact of Chemotherapy-Induced Peripheral Neuropathy on Treatment Delivery in Nonmetastatic Breast Cancer

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer;Journal of Clinical Oncology;2024-08-20

2. Prevention of paclitaxel-induced peripheral neuropathy: literature review of potential pharmacological interventions;Future Journal of Pharmaceutical Sciences;2024-05-06

3. Genetic determinants of taxane-induced peripheral neuropathy;Bratislava Medical Journal;2024

4. Evolution of predictive risk factor analysis for chemotherapy-related toxicity;Supportive Care in Cancer;2023-09-29

5. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes;Journal of the National Comprehensive Cancer Network;2023-02